[go: up one dir, main page]

NO20080801L - Aerosolformulering for inhalering av beta-agonister - Google Patents

Aerosolformulering for inhalering av beta-agonister

Info

Publication number
NO20080801L
NO20080801L NO20080801A NO20080801A NO20080801L NO 20080801 L NO20080801 L NO 20080801L NO 20080801 A NO20080801 A NO 20080801A NO 20080801 A NO20080801 A NO 20080801A NO 20080801 L NO20080801 L NO 20080801L
Authority
NO
Norway
Prior art keywords
inhalation
aerosol formulation
beta agonists
formula
agonists
Prior art date
Application number
NO20080801A
Other languages
English (en)
Other versions
NO343363B1 (no
Inventor
Barbara Niklaus-Humke
Michael Nowak
Kirsten Radau
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35241312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080801(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20080801L publication Critical patent/NO20080801L/no
Publication of NO343363B1 publication Critical patent/NO343363B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Oppfinnelsen angår en aerosolformulering for. inhalering, som er uten drivmiddel og som inneholder én eller flere forbindelser med den generelle formel (1) og et ytterligere virkestoff (2). I den nevnte formel kan gruppene R, R, Rog XT være definert som omtalt i kravene og beskrivelsen.
NO20080801A 2005-10-10 2008-02-14 Medikamentformulering, anvendelse av medikamentformuleringen for fremstilling av et farmasøytisk preparat for behandling av respiratoriske sykdommer og inhalasjonssett inneholdende samme NO343363B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05109376 2005-10-10
PCT/EP2006/067126 WO2007042468A2 (de) 2005-10-10 2006-10-06 Aerosolformulierung für die inhalation von betaagonisten

Publications (2)

Publication Number Publication Date
NO20080801L true NO20080801L (no) 2008-04-29
NO343363B1 NO343363B1 (no) 2019-02-11

Family

ID=35241312

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080801A NO343363B1 (no) 2005-10-10 2008-02-14 Medikamentformulering, anvendelse av medikamentformuleringen for fremstilling av et farmasøytisk preparat for behandling av respiratoriske sykdommer og inhalasjonssett inneholdende samme

Country Status (31)

Country Link
US (3) US20070088030A1 (no)
EP (1) EP1940349B1 (no)
JP (1) JP2009511542A (no)
KR (1) KR20080059290A (no)
CN (1) CN101282712A (no)
AR (1) AR058082A1 (no)
AU (1) AU2006301330B9 (no)
BR (1) BRPI0617278A2 (no)
CA (1) CA2624786C (no)
CY (1) CY1120199T1 (no)
DK (1) DK1940349T3 (no)
EA (1) EA200800927A1 (no)
EC (1) ECSP088294A (no)
ES (1) ES2668364T3 (no)
HR (1) HRP20180713T1 (no)
HU (1) HUE039186T2 (no)
IL (1) IL190682A (no)
LT (1) LT1940349T (no)
MY (1) MY163503A (no)
NO (1) NO343363B1 (no)
NZ (1) NZ567545A (no)
PE (1) PE20070708A1 (no)
PL (1) PL1940349T3 (no)
PT (1) PT1940349T (no)
RS (1) RS57085B1 (no)
SI (1) SI1940349T1 (no)
TW (1) TWI389692B (no)
UA (1) UA99250C2 (no)
UY (1) UY29844A1 (no)
WO (1) WO2007042468A2 (no)
ZA (1) ZA200801390B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
EP1917253B1 (de) * 2005-08-15 2015-01-07 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von betamimetika
CA2738616A1 (en) * 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
WO2010057928A1 (en) * 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta agonists
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
EP2906218B1 (en) 2012-10-09 2016-12-14 Boehringer Ingelheim International GmbH Beta-2-adrenoceptor agonist for the treatment of cough
US20140235627A1 (en) * 2012-12-21 2014-08-21 Boehringer Ingelheim International Gmbh ß2-ADRENOCEPTOR AGONIST FOR IMPROVEMENT OF EXERCISE TOLERANCE
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
CA2986839C (en) * 2015-05-18 2021-06-15 Glenmark Specialty S.A. Tiotropium inhalation solution for nebulization
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
CN115397417A (zh) * 2020-04-16 2022-11-25 广州谷森制药有限公司 含有噻托溴铵和奥达特罗的可吸入溶液制剂
CN115703121A (zh) * 2021-08-07 2023-02-17 广州谷森制药有限公司 一种含噻托溴铵、奥达特罗药品制剂和除醛包材容器的组合
CN114259481A (zh) * 2021-11-26 2022-04-01 南京华盖制药有限公司 一种奥达特罗复方吸入溶液

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
RO117414B1 (ro) * 1992-12-09 2002-03-29 Jager Paul D Waterbury Compozitie farmaceutica de aerosol in solutie
AU5629301A (en) * 2000-04-27 2001-11-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel, slow-acting betamimetics, a method for their production and their use as medicaments
DE10216036A1 (de) 2002-04-11 2003-10-23 Boehringer Ingelheim Pharma Aerosolformulierung für die Inhalation enthaltend ein Tiotropiumsalz
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7244728B2 (en) * 2004-03-17 2007-07-17 Boehringer Ingelheim International Gmbh Long acting betamimetics for the treatment of respiratory diseases
US20050272726A1 (en) * 2004-04-22 2005-12-08 Boehringer Ingelheim International Gmbh Novel medicaments for the treatment of respiratory diseases
US20050239778A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
PL2422786T3 (pl) * 2004-04-22 2015-02-27 Boehringer Ingelheim Int Nowe kombinacje środków leczniczych do leczenia chorób dróg oddechowych
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists

Also Published As

Publication number Publication date
TW200730178A (en) 2007-08-16
JP2009511542A (ja) 2009-03-19
BRPI0617278A2 (pt) 2011-07-19
US20070088030A1 (en) 2007-04-19
US20100009984A1 (en) 2010-01-14
AR058082A1 (es) 2008-01-23
EA200800927A1 (ru) 2008-10-30
DK1940349T3 (en) 2018-05-28
AU2006301330B2 (en) 2012-11-22
CA2624786A1 (en) 2007-04-19
CN101282712A (zh) 2008-10-08
EP1940349B1 (de) 2018-02-14
HRP20180713T1 (hr) 2018-06-15
WO2007042468A2 (de) 2007-04-19
CY1120199T1 (el) 2018-12-12
UY29844A1 (es) 2007-05-31
EP1940349A2 (de) 2008-07-09
AU2006301330A1 (en) 2007-04-19
IL190682A (en) 2015-06-30
UA99250C2 (ru) 2012-08-10
ZA200801390B (en) 2009-01-28
KR20080059290A (ko) 2008-06-26
US20110190284A1 (en) 2011-08-04
PT1940349T (pt) 2018-04-30
ES2668364T3 (es) 2018-05-17
NZ567545A (en) 2011-07-29
PL1940349T3 (pl) 2018-07-31
PE20070708A1 (es) 2007-08-06
IL190682A0 (en) 2008-11-03
AU2006301330B9 (en) 2013-01-17
HUE039186T2 (hu) 2018-12-28
MY163503A (en) 2017-09-15
RS57085B1 (sr) 2018-06-29
CA2624786C (en) 2015-06-16
WO2007042468A3 (de) 2007-08-02
SI1940349T1 (en) 2018-05-31
NO343363B1 (no) 2019-02-11
LT1940349T (lt) 2018-05-10
ECSP088294A (es) 2008-04-28
TWI389692B (zh) 2013-03-21

Similar Documents

Publication Publication Date Title
NO20080801L (no) Aerosolformulering for inhalering av beta-agonister
NO20090410L (no) Aerosolformuleringer for inhalaering av beta-agonister
NO20090407L (no) Aerosolformulering for inhalering av beta agonister
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
NO20050828L (no) lndol-3-svovelderivater
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
WO2008009379A3 (de) Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
ATE433447T1 (de) Pyrimiidinverbindungen
NO20064584L (no) Tetrahydropyridoindolderivater
NO20070866L (no) Antivirale forbindelser.
WO2007125103A3 (en) Benzamide glucokinase activators
NO20082496L (no) Pyrazinderivater
EP2023724B8 (de) Synergistische wirkstoffkombinationen
EP2702988A3 (en) Novel compositions and methods for treating hyperproliferative diseases
NZ592429A (en) PHENANTHROINDOLIZIDINE DERIVATIVE AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
IL188092A0 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
WO2006110173A3 (en) Novel compounds
NO20080839L (no) Isotopsubstituerte protonpumpeinhibitorer
MY146775A (en) Amino alcohol derivative and immunosuppressive agent having same as an active ingredient